Clinical data | |
---|---|
Trade names | Plaquenil, others |
Other names | HCQ |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601240 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Variable (74% on average) |
Protein binding | 45% |
Metabolism | Liver |
Elimination half-life | 32–50 days |
Excretion | Mostly kidney (23–25% as unchanged drug), also biliary (<10%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.003.864 |
Chemical and physical data | |
Formula | C18H26ClN3O |
Molar mass | 335.88 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Hydroxychloroquine, sold under the brand name Plaquenil among others, is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth, often in the form of hydroxychloroquine sulfate.[3]
Common side effects may include vomiting, headache, blurred vision, and muscle weakness.[3] Severe side effects may include allergic reactions, retinopathy, and irregular heart rate.[3][4] Although all risk cannot be excluded, it remains a treatment for rheumatic disease during pregnancy.[5] Hydroxychloroquine is in the antimalarial and 4-aminoquinoline families of medication.[3]
Hydroxychloroquine was approved for medical use in the United States in 1955.[3] It is on the World Health Organization's List of Essential Medicines.[6] In 2022, it was the 112th most commonly prescribed medication in the United States, with more than 5 million prescriptions.[7][8]
Hydroxychloroquine has been studied for an ability to prevent and treat coronavirus disease 2019 (COVID-19), but clinical trials found it ineffective for this purpose and a possible risk of dangerous side effects.[9] Among studies that deemed hydroxychloroquine intake to cause harmful side effects, a publication by The Lancet was retracted due to data flaws.[10] The speculative use of hydroxychloroquine for COVID-19 threatens its availability for people with established indications.[11]
mayoclinic1
was invoked but never defined (see the help page).Juurlink2020
was invoked but never defined (see the help page).